Benefits
Small blood pressure change, studied in people already on hypertension medication
This was studied in people already diagnosed with Grade I high blood pressure who were already taking prescription blood pressure medication, not in healthy adults. Over 12 weeks, 250 mg/day was linked to very small extra changes versus placebo: about 1.8 mmHg systolic (95% confidence interval 0.7 to 4.1) and 1.5 mmHg diastolic (95% confidence interval 0.3 to 3.0). A change that small is nowhere near what blood pressure medication does and would not be noticeable to an individual. The same trial found no change in blood vessel lining (endothelial) function and no change in inflammatory markers. It was funded by Pharmactive Biotech, the company that makes the ingredient, and three of the authors were employed by or affiliated with Pharmactive. Nobody should change, reduce or stop prescribed blood pressure treatment based on this.
Blood pressure findings in people with high cholesterol
A separate crossover trial was run in adults diagnosed with moderately high cholesterol. It reported a modest drop in diastolic blood pressure versus placebo, concentrated in men, so the finding is subgroup dependent rather than a general effect. That trial was industry funded and used an aged garlic extract standardized to S-allyl-cysteine rather than ABG10+ specifically, so it supports the ingredient category and not this brand in particular. Comparing effect sizes across the two trials is not meaningful, because they used different designs in different groups of patients.
Nitric oxide: a lab reading, not a measured health outcome
Blood tests in the hypertension trial suggested a rise in nitric oxide, a molecule the body makes that helps blood vessels relax. This is a laboratory measurement, not a health outcome. The same trial specifically measured how well the blood vessel lining actually worked and found no improvement, so the nitric oxide reading did not translate into better vessel function in the people studied.
ACE: a secondary lab marker, not a drug-like effect
The hypertension trial also tracked angiotensin-converting enzyme (ACE), a lab marker involved in tightening blood vessels. Any change here is a secondary laboratory reading taken in people who were already on prescription medication, and it does not mean the extract works like an ACE inhibitor drug. In that same trial the actual blood pressure difference versus placebo was under 2 mmHg, so this should not be read as a drug-like effect.
HDL functionality improvement
This comes from an exploratory re-analysis of the same hypertension trial, posted as a preprint that has not been peer reviewed, published in a journal, or included in this page's reference list. It described shifts in the make-up of large HDL particles. Whether particle-level shifts like these change anyone's health is unknown. Separately, a published 12-week trial of generic aged black garlic in 60 adults with mildly high cholesterol reported modest increases in HDL cholesterol, and that study did not test ABG10+.
VLDL particle findings, exploratory and unconfirmed
The same unpublished preprint re-analysis also reported lower cholesterol content in the largest VLDL particles. Subgroup results like this one, identified after the fact using clustering methods in a small group of people with medication-treated high blood pressure, are hypothesis generating only. They have not been peer reviewed and have not been tested in a trial designed to confirm them.
No unpleasant garlic odor or taste
The aging process removes most of the sharp smell and taste of raw garlic. Aged black garlic has a mild, sweet flavor and does not cause the garlic breath that puts many people off raw garlic supplements. This is a comfort and convenience point rather than a health benefit.
Mechanism of action
S-allyl cysteine (SAC) bioactivity
SAC is a stable, well absorbed sulfur compound in aged black garlic and is the marker the branded extract is standardized to. Most of what is known about it comes from laboratory and animal work rather than human outcome trials. SAC is generated during the controlled aging process from γ-glutamylcysteine precursors in raw garlic. Distinct from allicin (the active in fresh garlic) which is unstable and degraded quickly.
Nitric oxide pathway enhancement
The proposed mechanism is a rise in nitric oxide, a molecule that helps blood vessels relax. In the human trial this was measured only as a blood marker, and that trial found no measurable improvement in how the blood vessel lining actually functioned and no change in inflammatory markers. So this pathway is proposed rather than demonstrated in people.
ACE inhibition
ACE is an enzyme that helps tighten blood vessels, and the hypertension trial tracked it as a laboratory marker. Putting this alongside prescription ACE inhibitor drugs is misleading: those drugs produce large, reliable blood pressure changes, while the measured difference in this trial was under 2 mmHg on top of the medication participants were already taking.
Antioxidant complex
ABG10+ contains a complex bioactive blend of antioxidants: polyphenols, flavonoids, melanoidins (generated during the Maillard reaction), and organosulfur compounds. Aging changes the antioxidant profile compared with fresh garlic. What that means for a person's health is not established: the trial in medication-treated high blood pressure found no change in inflammatory markers, and antioxidant readings in a test tube or in blood are not the same as a health outcome.
Lipoprotein subclass remodeling
An unpublished preprint re-analysis of the hypertension trial described changes in the make-up of HDL and large VLDL particles. It has not been peer reviewed, the analysis was exploratory, and there is no evidence yet that these particle-level changes affect anyone's health.
Clinical trials
Randomized, triple-blind, placebo-controlled parallel trial conducted at Hospital Universitari Arnau de Vilanova (Lleida, Spain). Published in Nutrients, 2023 (PMID 37686723). Funded by Pharmactive Biotech, the company that makes the ingredient, and three of the authors were employed by or affiliated with Pharmactive. Participants stayed on their prescription blood pressure drugs throughout, so this tested the extract as an add-on.
77 Grade-1 hypertension patients receiving prescribed antihypertensive drug therapy. 12-week intervention.
Over 12 weeks at 250 mg/day (0.25 mg SAC), the average difference versus placebo was about 1.8 mmHg systolic (95% confidence interval 0.7 to 4.1) and 1.5 mmHg diastolic (95% confidence interval 0.3 to 3.0). Those are very small numbers, and they were measured on top of the prescription blood pressure drugs every participant was already taking. The trial also reported null results that matter: no change in blood vessel lining (endothelial) function and no change in inflammatory markers. Blood readings for nitric oxide and ACE activity moved, but those are laboratory measures, not health outcomes. The trial was manufacturer funded with manufacturer-affiliated authors, and it does not establish that this extract treats or manages high blood pressure.
Randomized, crossover, double-blind, controlled trial in adults diagnosed with moderately high cholesterol. Published in Nutrients, 2022 (PMID 35276764). Industry funded. The product tested was an aged garlic extract standardized to S-allyl-cysteine, not ABG10+ specifically, so this is category evidence rather than brand evidence.
Adults with moderately elevated cholesterol levels. Crossover protocol.
The trial reported a modest reduction in diastolic blood pressure versus placebo, with the effect concentrated in men. Results were modest and subgroup dependent. It did not establish broad cardiovascular risk reduction, and because participants were selected for high cholesterol the findings describe that group rather than healthy adults.
Sub-analysis of the Grade-1 hypertension clinical trial using NMR spectroscopy for detailed lipoprotein subclass and composition analysis. Posted as a medRxiv preprint (doi: 10.64898/2026.04.20.26351262v1). A preprint has not been peer reviewed and this one is not among the page's cited PubMed references. The 'responder' subgroups were found by applying clustering methods to the data after the fact, which is exploratory and can produce patterns by chance.
75 Grade-1 hypertensive participants from the pivotal trial. 12-week intervention.
The re-analysis described lower total lipoprotein particle numbers and changes in the composition of large VLDL and HDL particles, plus larger changes in triglycerides and VLDL lipids in a subgroup with worse baseline metabolic profiles. None of this has been peer reviewed, the subgroups were identified after the data were collected, and no health outcomes were measured. Treat it as a question for future research, not as evidence of benefit.